Helus Pharma Closes $50 Million Underwritten Offering

MT Newswires Live

06/25

Helus Pharma (HELP) closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.

The company said it paid underwriters a $3 million cash commission.

Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.

The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.

Shares of the company were up 4% in early Thursday trading.

Price: 5.38, Change: +0.29, Percent Change: +5.70

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2646070805"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2646070805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2646070805?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646070805","market":"us","top_or_hot":-1,"title":"Helus Pharma Closes $50 Million Underwritten Offering","media":"MT Newswires Live","content":"<html><body><p> Helus Pharma (HELP) closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.</p><p>The company said it paid underwriters a $3 million cash commission.</p><p>Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.</p><p>The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.</p><p>Shares of the company were up 4% in early Thursday trading.</p><p>Price: 5.38, Change: +0.29, Percent Change: +5.70</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Helus Pharma Closes $50 Million Underwritten Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHelus Pharma Closes $50 Million Underwritten Offering\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-25 21:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Helus Pharma (HELP) closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.</p><p>The company said it paid underwriters a $3 million cash commission.</p><p>Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.</p><p>The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.</p><p>Shares of the company were up 4% in early Thursday trading.</p><p>Price: 5.38, Change: +0.29, Percent Change: +5.70</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HELP","symbol_name":"Cybin Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2646070805","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646070805","pubTimestamp":1782395442,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Helus Pharma  closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.The company said it paid underwriters a $3 million cash commission.Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.Shares of the company were up 4% in early Thursday trading.Price: 5.38, Change: +0.29, Percent Change: +5.70","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HELP":"Cybin Inc","BK4007":"制药"},"translate_title":"Helus Pharma完成5000万美元承销发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HELP":1},"content_text":"Helus Pharma (HELP) closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.The company said it paid underwriters a $3 million cash commission.Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.Shares of the company were up 4% in early Thursday trading.Price: 5.38, Change: +0.29, Percent Change: +5.70","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}